StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Juno Therapeutics (JUNO) CEO Bishop: Second JCAR015 Patient with Brain Swelling has Died - Conf. call
November 23, 2016 8:44 AM
Juno Therapeutics (NASDAQ: JUNO) CEO Hans Bishop said that the second JCAR015 patient with brain swelling has died, according ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Trader Talk
Next Articles
SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold
November 25, 2016 6:48 AM
Juno Therapeutics (JUNO) PT Lowered to $34 at Maxim Group
November 23, 2016 1:51 PM
bluebird bio (BLUE) Falls 5% on Juno Clinical Hold
November 23, 2016 8:42 AM
Juno Therapeutics (JUNO) Sinks 40% as Trading Resumes after Clinical Hold
November 23, 2016 8:33 AM
Juno Therapeutics (JUNO) to Resume Trading at 8:30AM ET after Clinical Hold Announced
November 23, 2016 8:05 AM
Kite Pharma (KITE) on Watch as Juno Trial Placed on Clinical Hold
November 23, 2016 8:02 AM
Juno Therapeutics (JUNO) Halted for News Release
November 23, 2016 8:01 AM
Juno Therapeutics (JUNO) JCAR015 Phase II ROCKET Trial Placed on Clinical Hold
November 23, 2016 8:01 AM
Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold
November 23, 2016 8:00 AM
